Adagene Inc ADR (ADAG) Stock Price, Quote & News

Company Profile

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/met...

Industry: Biotechnology

Sector: Healthcare

Phone: 86 512 8777 3632

Website: www.adagene.com

Address:

Building C14, 4th Floor No. 218, Xinghu Street Suzhou Industrial Park, Suzhou, China

SuperGreenToday Apr. 17 at 5:09 PM

$ADAG

0 · Reply

OfficialStocktwitsUser Apr. 14 at 9:42 PM

$ADAG RSI: 52.86, MACD: 0.1484 Vol: 0.26, MA20: 3.95, MA50: 3.45 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

erevnon Apr. 6 at 1:29 PM

Guggenheim maintains Adagene $ADAG at Buy and raises the price target from $9 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

DARKP00L Apr. 6 at 11:59 AM

$ADAG 07:55 on Apr. 06 2026 Guggenheim Maintains Buy on Adagene, Raises Price Target to $10 #tradeideas

0 · Reply

BioTuesdays Apr. 2 at 12:49 PM

$ADAG and Incyte $INCY have announced a clinical collaboration to evaluate the combination of muzastotug (ADG126) and INCA33890, a TGFβR2 × PD-1 bispecific antibody, in patients with microsatellite stable colorectal cancer (MSS CRC) with or without liver metastases. https://biotuesdays.com/2026/04/02/adagene-and-incyte-collaborate-to-evaluate-combination-therapy-in-mss-crc-patients/

0 · Reply

DonCorleone77 Apr. 2 at 12:23 PM

$ADAG Adagene 18.666M share Spot Secondary priced at $3.75 Leerink and LifeSci Capital acted as joint book running managers for the offering.

0 · Reply

StocktwitsNews Apr. 2 at 12:01 PM

Why Is ADAG Stock Tanking Pre-Market Today? $ADAG $PGJ https://stocktwits.com/news/equity/markets/why-is-adag-stock-tanking-today/cZ7xrbYRI8E

0 · Reply

focafoca99 Mar. 17 at 9:38 PM

$ADAG is getting two AACR presentations for ADG126, and the Morpheus Liver combo arm is probably the piece people will focus on first.

0 · Reply

StockScanners Mar. 12 at 3:34 AM

$ADAG keep watch if this holds above 3.22

0 · Reply

StockJelli Mar. 11 at 4:18 PM

Hope you all are making profits despite a slightly down market. Here are the top momentum stocks above an mcap of $100M $OCGN $ADAG $NVTS $HIMS $UAMY

0 · Reply

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types

Apr 14, 2026, 7:00 AM EDT - 11 days ago

Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board

Apr 2, 2026, 7:10 AM EDT - 23 days ago

Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs

Apr 2, 2026, 7:01 AM EDT - 23 days ago

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

Apr 2, 2026, 7:00 AM EDT - 23 days ago

Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response

Apr 1, 2026, 5:00 PM EDT - 23 days ago

Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

Mar 17, 2026, 4:35 PM EDT - 5 weeks ago

Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA

Feb 17, 2026, 9:27 AM EST - 2 months ago

Adagene to Participate in Two Upcoming Investor Conferences

Jan 23, 2026, 8:00 AM EST - 3 months ago

Adagene Provides Business Update and 2026 Objectives

Dec 16, 2025, 7:00 AM EST - 4 months ago

Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)

Nov 13, 2025, 7:00 AM EST - 5 months ago

Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Oct 31, 2025, 7:00 AM EDT - 6 months ago

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

Sep 16, 2025, 8:00 AM EDT - 7 months ago

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

Sep 5, 2025, 9:55 AM EDT - 8 months ago

Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China

Sep 3, 2025, 9:05 AM EDT - 8 months ago

Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

Aug 26, 2025, 8:05 AM EDT - 8 months ago

Adagene to Participate in Two Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 9 months ago

Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates

Jul 15, 2025, 7:00 AM EDT - 10 months ago

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

Jul 8, 2025, 7:00 AM EDT - 10 months ago

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

Jul 1, 2025, 7:00 AM EDT - 10 months ago

Adagene announces up to $25 million strategic investment from Sanofi

May 27, 2025, 7:30 AM EDT - 11 months ago

Adagene to Present at Jefferies Global Healthcare Conference 2025

May 22, 2025, 5:05 PM EDT - 1 year ago

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

Apr 23, 2025, 10:05 AM EDT - 1 year ago

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

Mar 6, 2025, 8:00 AM EST - 1 year ago

Adagene to Present at Leerink's Global Healthcare Conference 2025

Feb 27, 2025, 8:00 AM EST - 1 year ago

Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer

Jan 29, 2025, 6:14 AM EST - 1 year ago

CD47 Inhibitor Drug Clinical Trials Market Opportunity Outlook 2028, Competitive Analysis of Adagene, ALX, ImmuneOncia, ImmuneOnco, Light Chain Bioscience, Phanes, and Virtuoso,

Jan 21, 2025, 5:00 PM EST - 1 year ago

Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium

Nov 7, 2024, 10:01 AM EST - 1 year ago

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 9, 2024, 6:00 AM EDT - 1 year ago

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Sep 16, 2024, 3:01 AM EDT - 1 year ago

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Jul 12, 2024, 7:00 AM EDT - 1 year ago

Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September

May 22, 2024, 4:45 PM EDT - 2 years ago

Adagene to Present at Investor Conferences in June

Mar 29, 2024, 9:00 AM EDT - 2 years ago

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 7, 2024, 4:01 PM EST - 2 years ago

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Feb 27, 2024, 8:00 AM EST - 2 years ago

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

Feb 9, 2024, 6:00 AM EST - 2 years ago

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl

Jan 16, 2024, 5:01 PM EST - 2 years ago

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Jan 4, 2024, 5:00 AM EST - 2 years ago

Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023

Oct 12, 2023, 8:00 AM EDT - 2 years ago

Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Sep 7, 2023, 6:00 AM EDT - 2 years ago

Adagene to Present at Investor and Scientific Conferences in September

Aug 31, 2023, 7:32 AM EDT - 2 years ago

Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update

May 4, 2023, 9:00 AM EDT - 3 years ago

Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate

Apr 28, 2023, 7:00 AM EDT - 3 years ago

Adagene Announces Updates to its Board of Directors

Apr 18, 2023, 9:17 AM EDT - 3 years ago

Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors

Mar 28, 2023, 4:30 PM EDT - 3 years ago

Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 14, 2023, 6:00 PM EDT - 3 years ago

Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April

SuperGreenToday Apr. 17 at 5:09 PM

$ADAG

0 · Reply

OfficialStocktwitsUser Apr. 14 at 9:42 PM

0 · Reply

erevnon Apr. 6 at 1:29 PM

Guggenheim maintains Adagene $ADAG at Buy and raises the price target from $9 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

DARKP00L Apr. 6 at 11:59 AM

$ADAG 07:55 on Apr. 06 2026 Guggenheim Maintains Buy on Adagene, Raises Price Target to $10 #tradeideas

0 · Reply

BioTuesdays Apr. 2 at 12:49 PM

0 · Reply

DonCorleone77 Apr. 2 at 12:23 PM

$ADAG Adagene 18.666M share Spot Secondary priced at $3.75 Leerink and LifeSci Capital acted as joint book running managers for the offering.

0 · Reply

StocktwitsNews Apr. 2 at 12:01 PM

Why Is ADAG Stock Tanking Pre-Market Today? $ADAG $PGJ https://stocktwits.com/news/equity/markets/why-is-adag-stock-tanking-today/cZ7xrbYRI8E

0 · Reply

focafoca99 Mar. 17 at 9:38 PM

$ADAG is getting two AACR presentations for ADG126, and the Morpheus Liver combo arm is probably the piece people will focus on first.

0 · Reply

StockScanners Mar. 12 at 3:34 AM

$ADAG keep watch if this holds above 3.22

0 · Reply

StockJelli Mar. 11 at 4:18 PM

Hope you all are making profits despite a slightly down market. Here are the top momentum stocks above an mcap of $100M $OCGN $ADAG $NVTS $HIMS $UAMY

0 · Reply

jacksparo Mar. 11 at 4:14 PM

$ADAG From my special list Nov Copy 2025! Today got to my projected exit at 4.50 From below 1.50 average entry! All documented ✅✅!

0 · Reply

topstockalerts Mar. 11 at 3:56 PM

$ADAG Following this closely as it continues to build momentum. Buyers are in control. Could be more upside ahead.

0 · Reply

SPARTANVI Mar. 11 at 3:10 PM

$AEHL 760k floater Compliance pr today Absolute bottom Potential reversal incoming like $ADAG 🇨🇳

1 · Reply

aquira Mar. 11 at 3:00 PM

$ADAG yessssiirrrr

0 · Reply

OfficialStocktwitsUser Feb. 28 at 4:15 AM

$ADAG RSI: 58.64, MACD: 0.2245 Vol: 0.24, MA20: 3.01, MA50: 2.37 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

VolatilityClustering Feb. 20 at 1:51 PM

$ADAG Adagene develops antibody-based cancer therapies. Clinical milestones drive valuation. Development risk remains elevated.

0 · Reply

SadyK189 Feb. 18 at 9:03 PM

Here is my Amazing daily "Stocktwits" report 1 / 2: $MLEC $VIVO $ATOM.X $ADAG MLEC: Price 8.02. My post was "Looking good on 4hours chart. Key support at 6.70 - 7.15. Next key level to test 9.40 - 9.80." It made a nice move to 19.50 today VVPR Price 2.10. My post was "Looking good on 4hours chart. Key support at 1.45 - 1.60. Next key level to test 2.65 - 2.9." It hit our desired zone and went till 3.34 today ATOM: Price 3.92. My post was "Looking good on 4hours chart. 3 - 3.30 is acting as key support zone. Next key level to test lies at 4.6 - 4.95." It made a nice move to 6.98 today ADAG Price 2.46. My post was "Looking good on daily chart. Key support at 1.80 - 2.05. Next key level to test is 3- 3.30." It hit our desired zone and went till 3.51 today

1 · Reply

jacksparo Feb. 18 at 4:42 PM

$ADAG In the right path from my Special list. My suggested entry last were among the best for this one so far up big here!

0 · Reply

SadyK189 Feb. 17 at 9:05 PM

Here is my Amazing daily Stocktwits report 2 / 2: $SIF $FSLY $ADAG $PLSE ADAG Price 2.46. My post was "Looking good on daily chart. Key support at 1.80 - 2.05. Next key level to test is 3- 3.30." It hit our desired zone and went till 3.44 today SIF Price 8.74. My post was "Looking good on daily chart. Key support at 7.3 - 7.8. Next key level to test is 9.75 - 10.30." It made a nice move to 13.37 today FSLY Price at 16.40. My post was"Looking good on 4hours chart. key support at 13.1 - 13.8. Next key level to test is 17.6 - 18.15." It hit our desired zone and went till 19.21 today PLSE My post was "Good close of daily candle. Key support at 17.3 - 17.85. Next key level to test is 22.9 - 24.1. Currently at 21.60" It went till 24.13 today

0 · Reply

jacksparo Feb. 17 at 6:58 PM

$CABA $ADAG They can’t beat me in those bios!!! Every thing as planned ✅✅! I am still sharing my live updates only in the Live Telegram biotech group 📈📈📈!

0 · Reply

SadyK189 Feb. 17 at 5:58 PM

$ADAG Price 2.46. My post was "Looking good on daily chart. Key support at 1.80 - 2.05. Next key level to test is 3- 3.30. Currently at 2.46" It hit our desired zone and at 3.24 now

0 · Reply

Market Cap	177.22M
Revenue (ttm)	7.67M
Net Income (ttm)	-17.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-229.60%
Debt to Equity Ratio	0.05

Volume	101,000
Avg Vol	262,426
Day's Range	N/A - N/A
Shares Out	47.39M
Stochastic %K	15%
Beta	0.58
Analysts	Strong Sell
Price Target	$9.40